Clinical Trial

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-19.
Status change: Not Yet Recruiting → Recruiting 2024-07-09
Trial Details
NCT Number NCT06378242
Lead Sponsor RemeGen Co., Ltd.
Conditions High-risk Non-muscle Invasive Bladder Cancer
Enrollment 24 participants
Start Date 2024-06-14
Primary Completion 2029-03-15 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-11